首页工具

登录

搜索结果

Search Results for " kras "

Targets Recommended: Apoptosis Ras

202

抑制剂 & 化合物

1

天然产物

1

化合物库

65

重组蛋白

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name
L2192	抗胰腺癌化合物库		2238 compounds
	2238 种与胰腺癌相关的化合物，可以用于高通量和高内涵筛选；

化合物库

抗胰腺癌化合物库

Cat.No: L2192

Compounds: 2238

Cat. No.	Product Name	Target	Signaling Pathways
T8756	KRAS inhibitor-9 DUN09716	Apoptosis; Ras	Apoptosis; GPCR/G Protein; MAPK
	KRAS inhibitor-9 (DUN09716) 是一种 KRAS 抑制剂，阻止 GTP-KRAS 的形成和 KRAS 下游激活。它以中等的结合亲和力与 KRAS G12D、KRAS G12C 和 KRAS Q61H 蛋白结合，选择性抑制具有 KRAS 突变的 NSC-LC 细胞的增殖。它可导致 G2/M 细胞周期停滞并诱导凋亡。
T40286	KRAS G12C inhibitor 19	Ras	GPCR/G Protein; MAPK
	KRAS G12C inhibitor 19 是一种有效的 KRAS G12C 抑制剂，在细胞实验中显示出抗肿瘤活性，科抑制肿瘤生长。
T78212	RMC-9805 KRAS G12D inhibitor 18,KRAS G12D IN 18	Others	Others
	RMC-9805为一种有效的 KRAS G12D 抑制剂，具有潜在的抗肿瘤和抑制肿瘤细胞增殖的活性，可用于研究胰腺癌。
T38936	KRAS G13D peptide, 25 mer KRAS G13D peptide, 25 mer
	KRAS G13D peptide, a 25-mer sequence, is derived from the KRAS activating oncogene mutation and serves as an immune potentiator. This peptide possesses immunogenic properties and can be utilized for the development of a KRAS vaccine.
T62228	KRAS G12D inhibitor 14	Ras	GPCR/G Protein; MAPK
	KRAS G12D inhibitor 14 是一种 KRAS G12D 的有效抑制剂，能够结合 KRAS G12D 蛋白 (Kd: 33 nM)。KRAS G12D inhibitor 14 抑制 KRAS G12D (KRAS G12D-GTP) 的活性形式，但对 KRAS G13D 无抑制作用。
T36761	KRAS inhibitor-10
	KRAS inhibitor-10 (WO2021005165 A1, compound 11) is a potent and selective inhibitor of RAS proteins, with a specific focus on KRAS proteins. This orally active anti-cancer agent demonstrates strong efficacy in cancer research, specifically in pancreatic cancer, breast cancer, multiple myeloma, leukemia, and lung cancer. KRAS inhibitor-10 is classified as a tetrahydroisoquinoline compound. Its inhibitory properties provide valuable insights and potential therapeutic applications in the field of ...
T40282	KRAS G12D inhibitor 7
	KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.
T11774	KRAS inhibitor-7	Ras	GPCR/G Protein; MAPK
	KRAS inhibitor-7 is a potent KRAS G12C inhibitor.
T11775	KRAS inhibitor-8	Ras	GPCR/G Protein; MAPK
	KRAS inhibitor-8 is a potent KRAS G12C inhibitor.
T11772	KRAS inhibitor-4	Others	Others
	KRAS inhibitor-4 developed as anticancer agents, is a potent KRAS inhibitor.
T77808	Kras binder 12
	Kras binder 12 可用于 Ras 相关研究。
T40285	KRAS G12C inhibitor 18
	KRAS G12C inhibitor 18 is a potent, orally active compound that inhibits KRAS G12C and exhibits anti-tumor activities.
T40281	KRAS G12D inhibitor 6
	KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D.
T40246	KRAS G12D inhibitor 5
	KRAS G12D inhibitor 5 is a KRAS G12D inhibitor for the potential treatment of pancreatic cancer.
T40272	KRAS mutant protein inhibitor 1
	KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor for potential treatment in cancer.
T11773	KRAS inhibitor-6	Ras	GPCR/G Protein; MAPK
	KRAS inhibitor-6 is a potent KRAS G12C inhibitor.
T77806	KRAS inhibitor FB9
	KRAS inhibitor FB9 可用于 Ras 相关研究。
T9674	KRAS G12D inhibitor 1
	KRAS G12D inhibitor 1 (例 243) 是一种KRAS G12D 抑制剂，对KRAS G12D 介导的 ERK 磷酸化的IC50值为0.8 nM。
T11778	KRas G12C inhibitor 3	Ras	GPCR/G Protein; MAPK
	KRas G12C inhibitor 3 is a compound that inhibits KRas G12C.
T11779	KRas G12C inhibitor 4	Ras	GPCR/G Protein; MAPK
	KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.
T11769	KRAS G12C inhibitor 15	Ras	GPCR/G Protein; MAPK
	KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor .
T11780	KRAS G12C inhibitor 5	Ras	GPCR/G Protein; MAPK
	KRAS G12C inhibitor 5 is a KRas G12C inhibitor.
T11771	KRAS G12C inhibitor 17	Ras	GPCR/G Protein; MAPK
	KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor.
T11770	KRAS G12C inhibitor 16	Ras	GPCR/G Protein; MAPK
	KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor.
T11777	KRas G12C inhibitor 2	Ras	GPCR/G Protein; MAPK
	KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.
T11768	KRAS G12C inhibitor 14	Ras	GPCR/G Protein; MAPK
	KRAS G12C inhibitor 14 是一种有效的 KRAS G12C 抑制剂（IC50= 18 nM）。
T11767	KRAS G12C inhibitor 13	Ras	GPCR/G Protein; MAPK
	KRAS G12C inhibitor 13 is a KRAS G12C inhibitor .
T11776	KRas G12C inhibitor 1	Ras	GPCR/G Protein; MAPK
	KRas G12C inhibitor 1 is a compound that inhibits KRas G12C.
T77802	KRAS G12C inhibitor 1R
	KRAS G12C inhibitor 1R 可用于 Ras 相关研究。
T77804	KRAS G12D mutation regulator 4
	KRAS G12D mutation regulator 4 可用于 Ras 相关研究。
T77805	KRAS G12C mutant protein inhibitor A-1
	KRAS G12C mutant protein inhibitor A-1 可用于 Ras 相关研究。
T78651	Glecirasib JAB-21822,KRAS G12C inhibitor 36	Ras	GPCR/G Protein; MAPK
	Glecirasib (KRAS G12C inhibitor 36) 作为潜在的KRAS G12C抑制剂，在Ras蛋白家族中发挥作用，对细胞内信号传递具重要影响，并在生长发育中扮演关键角色。本化合物显示出研究KRAS G12C介导的癌症潜力。
T72659	KRAS inhibitor-3
	KRAS inhibitor-3，一种高效KRAS抑制剂，具有强大的亲和力，能够与野生型及致癌型KRAS突变体紧密结合（KD值：KRAS WT为0.28 μM，KRAS G12C为0.63 μM，KRAS G12D为0.37 μM，KRAS Q61H为0.74 μM）。该化合物还能干扰KRAS与Raf之间的相互作用。
T72599	KRAS inhibitor-11
	KRAS inhibitor-11 是一种 KRAS 抑制剂。
T63235	KRAS inhibitor-14
	KRAS inhibitor-14 是 KRAS G12C 的有效抑制剂(IC50: 0.249 μM)。KRAS inhibitor-14 在 MIA PaCA-2，A549 细胞中表现出 p-ERK 抑制作用，IC50s 分别为 1.12，>33.3 μM。KRAS inhibitor-14 对胰腺癌、结直肠癌和肺癌的具有研究潜力。
T63928	KRAS inhibitor-21
	KRAS inhibitor-21 (22b) 是 KRAS G12C 抑制剂 (IC50<0.01 μM)，能够用于研究癌症。
T62737	KRAS inhibitor-15
	KRAS inhibitor-15 (compound 3-19) 是一种 KRAS G12C 的有效抑制剂 (IC50: 0.954 μM)。KRAS inhibitor-15 在 MIA PaCA-2，A549 细胞中表现出 p-ERK 抑制作用，IC50s 分别为 2.03，>33.3 μM。KRAS inhibitor-15 具有潜力进行胰腺癌、结直肠癌和肺癌的研究。
T63164	KRAS inhibitor-13
	KRAS inhibitor-13 (compound 5-6) 是一种 KRAS G12C 的有效抑制剂 (IC50: 0.883 μM)。KRAS inhibitor-13 在 MIA PaCA-2，A549 细胞中具有 p-ERK 抑制效果，其 IC50 值分别为 5.9，>100 μM。 KRAS inhibitor-13 具有潜力进行胰腺癌、结直肠癌和肺癌的研究。
T79147	KRAS degrader-1
	KRAS degrader-1（compound 1）是通过自噬-溶酶体途径降解特定蛋白的高效KRAS降解剂。
T62751	KRAS inhibitor-12
	KRAS inhibitor-12 (compound 6-1) 是一种 KRAS G12C 的有效抑制剂 (IC50: 0.537 μM)。KRAS inhibitor-12 在 MIA PaCA-2，A549 细胞中表现出 p-ERK 抑制作用，其 IC50 值分别为 1.3，3.7 μM。 KRAS inhibitor-12 具有潜力进行胰腺癌，结直肠癌和肺癌的研究。
T62981	KRAS inhibitor-17
	KRAS inhibitor-17 (compound 3-9) 是一种 KRAS G12C 的有效抑制剂 (IC50: 3.37 μM)。KRAS inhibitor-17 具有 p-ERK 抑制作用，在 MIA PaCA-2 细胞的 IC50=9.25 μM，在 A549 细胞中的 IC50 >33.3 μM。KRAS inhibitor-17 具有潜力进行胰腺癌，结直肠癌和肺癌的研究。
T62752	KRAS inhibitor-16
	KRAS inhibitor-16 (compound 3-11) 是一种 KRAS G12C 的有效抑制剂 (IC50: 0.457 μM)。KRAS inhibitor-16 在 MIA PaCA-2，A549 细胞中表现出 p-ERK 抑制作用，IC50s 分别为 3.06，11.1 μM。 KRAS inhibitor-16 具有潜力进行胰腺癌，结直肠癌和肺癌的研究。
T62784	KRAS inhibitor-18
	KRAS inhibitor-18 (compound 3-10) 是一种 KRAS G12C 的有效抑制剂 (IC50: 4.74 μM)。KRAS inhibitor-18 在 MIA PaCA-2，A549 细胞中表现出 p-ERK 抑制作用，IC50s 分别为 66.4，11.1 μM。KRAS inhibitor-18 具有潜力进行胰腺癌、结直肠癌和肺癌的研究。
T79800	pan-KRAS-IN-2	Ras	GPCR/G Protein; MAPK
	Pan-KRAS-IN-2（compound 6）是一种抑制剂，对KRAS WT及其多种突变体（G12D、G12C、G12V、G12S、G12A、Q61H）表现出极高的抑制活性，其IC50均不超过10 nM；然而对KRAS G13D的抑制活性较低，IC50超过10 μM。
T79799	pan-KRAS-IN-4	Ras	GPCR/G Protein; MAPK
	Pan-KRAS-IN-4 (compound 5) 为一种高效KRAS抑制剂，其IC50值分别为0.37 nM (Kras G12C) 和0.19 nM (Kras G12V)。
T79814	pan-KRAS-IN-3	Ras	GPCR/G Protein; MAPK
	Pan-KRAS-IN-3 (Example 84)为一款pan-KRAS抑制剂，适用于癌症研究领域。
T79162	SOS1/KRAS-IN-1	Ras	GPCR/G Protein; MAPK
	SOS1/KRAS-IN-1(Compound 2)为针对SOS1/KRAS介导的疾病进行研究而设计的抑制剂。
T63926	KRAS G12C inhibitor 22
	KRAS G12C inhibitor 22 是 KRAS G12C 抑制剂。
T72346	KRAS G12C inhibitor 20
	KRAS G12C inhibitor 20 是一种KRAS G12C 的抑制剂。
T64033	KRAS G12C inhibitor 34
	KRAS G12C inhibitor 34 是一种 KRAS G12C 的抑制剂，能够用于研究癌症研究。

化合物

KRAS inhibitor-9

Cat.No: T8756

Synonym: DUN09716

Target: Apoptosis, Ras

KRAS G12C inhibitor 19

Cat.No: T40286

Target: Ras

Cat.No: T78212

Synonym: KRAS G12D inhibitor 18,KRAS G12D IN 18

Target: Others

KRAS G13D peptide, 25 mer

Cat.No: T38936

Synonym: KRAS G13D peptide, 25 mer

KRAS G12D inhibitor 14

Cat.No: T62228

Target: Ras

KRAS inhibitor-10

Cat.No: T36761

KRAS G12D inhibitor 7

Cat.No: T40282

KRAS inhibitor-7

Cat.No: T11774

Target: Ras

KRAS inhibitor-8

Cat.No: T11775

Target: Ras

KRAS inhibitor-4

Cat.No: T11772

Target: Others

Kras binder 12

Cat.No: T77808

KRAS G12C inhibitor 18

Cat.No: T40285

KRAS G12D inhibitor 6

Cat.No: T40281

KRAS G12D inhibitor 5

Cat.No: T40246

KRAS mutant protein inhibitor 1

Cat.No: T40272

KRAS inhibitor-6

Cat.No: T11773

Target: Ras

KRAS inhibitor FB9

Cat.No: T77806

KRAS G12D inhibitor 1

Cat.No: T9674

KRas G12C inhibitor 3

Cat.No: T11778

Target: Ras

KRas G12C inhibitor 4

Cat.No: T11779

Target: Ras

KRAS G12C inhibitor 15

Cat.No: T11769

Target: Ras

KRAS G12C inhibitor 5

Cat.No: T11780

Target: Ras

KRAS G12C inhibitor 17

Cat.No: T11771

Target: Ras

KRAS G12C inhibitor 16

Cat.No: T11770

Target: Ras

KRas G12C inhibitor 2

Cat.No: T11777

Target: Ras

KRAS G12C inhibitor 14

Cat.No: T11768

Target: Ras

KRAS G12C inhibitor 13

Cat.No: T11767

Target: Ras

KRas G12C inhibitor 1

Cat.No: T11776

Target: Ras

KRAS G12C inhibitor 1R

Cat.No: T77802

KRAS G12D mutation regulator 4

Cat.No: T77804

KRAS G12C mutant protein inhibitor A-1

Cat.No: T77805

Cat.No: T78651

Synonym: JAB-21822,KRAS G12C inhibitor 36

Target: Ras

KRAS inhibitor-3

Cat.No: T72659

KRAS inhibitor-11

Cat.No: T72599

KRAS inhibitor-14

Cat.No: T63235

KRAS inhibitor-21

Cat.No: T63928

KRAS inhibitor-15

Cat.No: T62737

KRAS inhibitor-13

Cat.No: T63164

KRAS degrader-1

Cat.No: T79147

KRAS inhibitor-12

Cat.No: T62751

KRAS inhibitor-17

Cat.No: T62981

KRAS inhibitor-16

Cat.No: T62752

KRAS inhibitor-18

Cat.No: T62784

pan-KRAS-IN-2

Cat.No: T79800

Target: Ras

pan-KRAS-IN-4

Cat.No: T79799

Target: Ras

pan-KRAS-IN-3

Cat.No: T79814

Target: Ras

SOS1/KRAS-IN-1

Cat.No: T79162

Target: Ras

KRAS G12C inhibitor 22

Cat.No: T63926

KRAS G12C inhibitor 20

Cat.No: T72346

KRAS G12C inhibitor 34

Cat.No: T64033

Cat. No.	Product Name	Target	Signaling Pathways
T5S0777	Phellodendrine chloride	Others	Others
	Phellodendrine chloride 是一种Phellodendron amurense 中的生物碱。它通过巨胞饮抑制营养物质的吸收，进而抑制 KRAS 突变的胰腺癌细胞的增殖。

天然产物

Phellodendrine chloride

Cat.No: T5S0777

Target: Others

Species：

Expression System：

Tag：

Cat. No.	Product Name	Species	Expression System
TMPY-06056	KRAS Protein, Human, Recombinant (G12D, His) KRAS1,K-RAS4B,Kirsten rat sarcoma viral oncogene ho...	Human	E. coli
	KRAS Protein, Human, Recombinant (G12D, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22 kDa and the accession number is P01116-2.
TMPY-01888	KRAS Protein,Human, Recombinant (Q61H, His) KRAS2,C-K-RAS,Kirsten rat sarcoma viral oncogene ho...	Human	E. coli
	KRAS Protein,Human, Recombinant (Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22.5 kDa and the accession number is P01116-2.
TMPY-04116	KRAS Protein,Human,Recombinant(G12C & Q61H, His) NS,CFC2,K-RAS4B,C-K-RAS,KRAS2,K-RAS2B,K-RAS,Kirsten...	Human	E. coli
	KRAS Protein,Human,Recombinant(G12C & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2.
TMPY-04113	KRAS Protein,Human,Recombinant(G12D & Q61H, His) Kirsten rat sarcoma viral oncogene homolog,KRAS2,KI...	Human	E. coli
	KRAS Protein,Human,Recombinant(G12D & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2.
TMPK-01488	HLA-A11:01&B2M&KRAS* WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi) K-RAS4A,MHC,GTPase Kras,K-Ras 2,KRAS2,K-RA...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01510	HLA-A03:01&B2M&KRAS* WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi) NS,NS3,KRAS2,RASK2,MHC,RALD,K-Ras 2,K-RAS4B,C-K-RAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01458	HLA-A11:01&B2M&KRAS* G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi) K-Ras 2,GTPase Kras,KRAS2,MHC,K-RAS4A,CFC2...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01399	HLA-A11:01&B2M&KRAS* WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-RAS2A,NS3,KRAS2,CFC2,K-RAS4B,GTPase Kras...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01479	HLA-A11:01&B2M&KRAS* WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated NS3,KRAS1,K-Ras 2,K-RAS2A,K-RAS2B,C-K-RAS,K-RAS4A,C...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01529	HLA-A11:01&B2M&KRAS* G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi) K-RAS4A,KRAS1,MHC,K-RAS2B,CFC2,GTPase Kras...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01463	HLA-A11:01&B2M&KRAS* G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi) C-K-RAS,KI-RAS,KRAS1,K-RAS4A,KRAS2,CFC2,MH...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01518	HLA-A11:01&B2M&KRAS* G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi) MHC,NS,KRAS1,K-RAS2A,GTPase Kras,KRAS<...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01527	HLA-A03:01&B2M&KRAS* G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi) NS,RALD,C-K-RAS,RASK2,K-RAS2B,KRAS2,KRAS,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01433	HLA-A11:01&B2M&KRAS* G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi) GTPase Kras,NS3,K-Ras 2,K-RAS2B,RALD,MHC,RASK2,K-RA...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01512	HLA-A03:01&B2M&KRAS* WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi) K-Ras 2,NS,NS3,K-RAS2B,CFC2,MHC,KRAS1,GTPase Kr...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01461	HLA-A11:01&B2M&KRAS* G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi) C-K-RAS,KRAS,RASK2,K-Ras 2,K-RAS2A,MHC,CFC2,K-RAS4B...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01434	HLA-A11:01&B2M&KRAS* G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi) RASK2,CFC2,GTPase Kras,KRAS,K-RAS2B,MHC,K-...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01451	HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi) NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01408	HLA-A02:01&B2M&KRAS* G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated RALD,KRAS1,KRAS2,K-RAS2B,CFC2,NS3,GTPase <...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01432	HLA-A11:01&B2M&KRAS* G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi) RASK2,K-RAS4A,K-RAS4B,KRAS2,CFC2,MHC,KRAS,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01511	HLA-A03:01&B2M&KRAS* WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated GTPase Kras,K-RAS4A,KI-RAS,K-RAS4B,C-K-RAS,K-Ras 2,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01401	HLA-A11:01&B2M&KRAS* WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) MHC,CFC2,K-Ras 2,RALD,K-RAS4A,NS,RASK2,GTPase Kras,...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01427	HLA-A11:01&B2M&KRAS* G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated C-K-RAS,K-RAS4B,GTPase Kras,K-RAS4A,K-RAS2A,KRA...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01525	HLA-A11:01&B2M&KRAS* G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3,GTPase Kras,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01428	HLA-A11:01&B2M&KRAS* G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi) CFC2,K-RAS4B,K-Ras 2,C-K-RAS,RASK2,NS3,RALD,KI-RAS,K-RAS2A,M...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01528	HLA-A11:01&B2M&KRAS* G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi) KRAS1,MHC,K-RAS2B,K-RAS4B,NS,GTPase Kras,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01465	HLA-A11:01&B2M&KRAS* G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi) NS3,K-RAS2A,CFC2,KRAS,GTPase Kras,K-RAS2B,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01507	HLA-A11:01&B2M&KRAS* G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi) K-RAS2A,K-RAS4B,KI-RAS,RALD,C-K-RAS,RASK2,NS,MHC,NS3,K-RAS4A...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01489	HLA-A11:01&B2M&KRAS* WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi) K-RAS2A,NS3,KRAS1,KRAS2,MHC,NS,K-RAS2B,K-R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01456	HLA-C03:04&B2M&KRAS* G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi) KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01462	HLA-A11:01&B2M&KRAS* G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-RAS4A,K-RAS2A,CFC2,KRAS1,K-RAS4B,C-K-RAS,KRAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01460	HLA-A11:01&B2M&KRAS* G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated MHC,K-RAS2A,KI-RAS,K-RAS4B,RALD,NS3,GTPase Kras,K-R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01403	HLA-A11:01&B2M&KRAS* G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) K-Ras 2,KI-RAS,CFC2,KRAS1,GTPase Kras,...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01407	HLA-A02:01&B2M&KRAS* WT (KLVVVGAGGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated KRAS2,RALD,C-K-RAS,NS3,MHC,CFC2,KRAS,KI-RA...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01438	HLA-A11:01&B2M&KRAS* WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled RASK2,KRAS2,KRAS1,MHC,C-K-RAS,KI-RAS,K-RAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01450	HLA-C03:04&B2M&KRAS* G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS2B,K-Ras ...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01526	HLA-A03:01&B2M&KRAS* G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi) KRAS,NS3,GTPase Kras,RASK2,K-RAS2B,C-K-RAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01490	HLA-A11:01&B2M&KRAS* G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi) K-RAS2A,GTPase Kras,K-Ras 2,RALD,KRAS2,K-R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01431	HLA-A11:01&B2M&KRAS* G12S (VVVGASGVGK) Tetramer Protein, Human, MHC (His & Avi) RALD,C-K-RAS,MHC,K-RAS2A,GTPase Kras,KRAS,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01429	HLA-A11:01&B2M&KRAS* G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated MHC,K-Ras 2,NS,K-RAS4A,KRAS,NS3,KI-RAS,K-RAS2A,K-RA...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01404	HLA-A11:01&B2M&KRAS* G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated NS,KRAS,KRAS1,KRAS2,MHC,RALD,K-RA...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01457	HLA-A11:01&B2M&KRAS* G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-Ras 2,CFC2,RALD,MHC,KRAS,K-RAS4B,NS3,C-K-RAS,NS,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01405	HLA-A11:01&B2M&KRAS* G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) KI-RAS,RASK2,K-Ras 2,MHC,KRAS,KRAS1,NS3,K-...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01443	HLA-A11:01&B2M&KRAS* G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled KRAS1,C-K-RAS,K-RAS4B,RALD,K-Ras 2,K-RAS2A,K-RAS2B,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01430	HLA-A11:01&B2M&KRAS* G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) K-RAS2A,RALD,NS3,K-Ras 2,KI-RAS,NS,MHC,K-RAS2B,K-RAS4A,K...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01440	HLA-A11:01&B2M&KRAS* G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled RASK2,KI-RAS,C-K-RAS,KRAS,MHC,NS,K-RAS4A,K-RAS2B,CF...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01435	HLA-A03:01&B2M&KRAS* G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled KRAS2,NS3,RASK2,KI-RAS,RALD,K-RAS2B,K-RAS4B,GTPase ...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01536	HLA-A11:01&B2M&KRAS* G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated NS3,MHC,KRAS,RALD,CFC2,K-RAS2B,GTPase Kras...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01464	HLA-A11:01&B2M&KRAS* G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated C-K-RAS,K-RAS4A,GTPase Kras,K-RAS2A,NS,K-RAS2B,MHC,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01453	HLA-A03:01&B2M&KRAS* G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated RASK2,CFC2,K-Ras 2,NS3,GTPase Kras,KRAS1,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
------------------------ 更多 ------------------------

重组蛋白

KRAS Protein, Human, Recombinant (G12D, His)

Cat.No: TMPY-06056

Species: Human

Expression System: E. coli

KRAS Protein,Human, Recombinant (Q61H, His)

Cat.No: TMPY-01888

Species: Human

Expression System: E. coli

KRAS Protein,Human,Recombinant(G12C & Q61H, His)

Cat.No: TMPY-04116

Species: Human

Expression System: E. coli

KRAS Protein,Human,Recombinant(G12D & Q61H, His)

Cat.No: TMPY-04113

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01488

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01510

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01458

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01399

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01479

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01529

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01463

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01518

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01527

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01433

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01512

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01461

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01434

Species: Human

Expression System: HEK293 Cells

HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01451

Species: Human

Expression System: HEK293 Cells

HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01408

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01432

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01511

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01401

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01427

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01525

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01428

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01528

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01465

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01507

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01489

Species: Human

Expression System: HEK293 Cells

HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01456

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01462

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01460

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01403

Species: Human

Expression System: E. coli

HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01407

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01438

Species: Human

Expression System: HEK293 Cells

HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01450

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01526

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01490

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01431

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01429

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01404

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01457

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01405

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled

Cat.No: TMPK-01443

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01430

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01440

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01435

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01536

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01464

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01453

Species: Human

Expression System: HEK293 Cells

--------- 更多 ---------

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4

沪公网安备 31010602006700号

沪公网安备 31010602006700号

TargetMol Loading

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼